Clarity Pharmaceuticals Ltd

ASX (AUD): Clarity Pharmaceuticals Ltd (CU6)

Last Price

5.68

Today's Change

-0.29 (4.85%)

Day's Change

5.61 - 6.07

Trading Volume

1,733,618

Overview

Market Cap

1 Billion

Shares Outstanding

320 Million

Avg Volume

1,962,150

Avg Price (50 Days)

7.36

Avg Price (200 Days)

5.23

PE Ratio

-35.50

EPS

-0.16

Earnings Announcement

22-Nov-2024

Previous Close

5.97

Open

6.00

Day's Range

5.61 - 6.07

Year Range

1.26 - 8.975

Trading Volume

1,733,618

Price Change Highlight

1 Day Change

-4.86%

5 Day Change

-20.89%

1 Month Change

-16.10%

3 Month Change

-17.56%

6 Month Change

39.56%

Ytd Change

169.19%

1 Year Change

333.59%

3 Year Change

499.75%

5 Year Change

278.67%

10 Year Change

278.67%

Max Change

278.67%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. The company has collaboration with GU Research Network for an investigator initiated Trial X-Calibur, using 64Cu-SAR-bisPSMA in known or suspected prostate cancer. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment